Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
The degree of semaglutide-induced weight loss in this study exceeded the EMA and FDAs criteria for anti-obesity drugs and there were no safety concerns, indicating the potential of once-daily subcutaneous semaglutide as an anti-obesity drug in the future
After approving oral Wegovy in December 2025, the FDA has now also approved Clinical trial data shows that participants taking Foundayo achieved meaningful weight loss compared with placebo, reinforcing its potential as an effective treatment option
Catch the full episode here
Structure Therapeutics Sector: Oral small molecule GLP-1 receptor agonists for obesity HQ: San Francisco, CA Year Founded: 2016 (as Eccogene
US$ 26.18
US$ 23.29
US$ 23.66
US$ 27.57
